Onset of E2 reduction (community report): Within 24-72 hours, similar to other AIs.

Subjective signs of appropriate dosing (when used in a high-E2 context):

• Reduction of nipple sensitivity / gyno tenderness on aromatizing AAS cycle
• Reduced water retention / "tighter, drier" appearance
• Sometimes reported "harder, more vascular" appearance attributed to lower subcutaneous water
• Improvement in libido when high E2 was the suppressor

Subjective signs of overdosing / E2 crash (universal across AI class, not arimistane-specific):

• Joint pain — knees, hands, hips, wrists — characteristic "dry joint" feeling within days of overshoot
• Libido collapse / erectile dysfunction — sudden loss of sexual interest
• Mood crash — anhedonia, irritability, low motivation — can mimic depression
• Fatigue + brain fog — "drained/empty" quality distinct from high-E2 fatigue
• Lipid disruption — LDL up, HDL down over weeks
• Bone density loss — silent, only visible on DEXA over months
• Mucosal / oral dryness, dry skin + paradoxical acne — T:E2 ratio shifts androgenic
• Recovery from E2 crash: stop arimistane → because suicide inhibitors require new enzyme synthesis for aromatase recovery, the rebound timeline may be longer than for reversible AIs (anastrozole/letrozole, ~7-14 days) — community reports suggest 1-3 weeks for full E2 recovery after arimistane discontinuation, though formal data is absent.

Important archetype-relevant caveat: All "subjective wins" listed above are wins relative to a high-E2 starting state (TRT, AAS, gyno). In a eugonadal young man with normal E2, the same drug effect produces only the crash phenotype — there is no high E2 to relieve, only normal E2 to suppress.

• Tolerance buildup: Minimal pharmacological tolerance; aromatase suppression scales with covalent inactivation of enzyme molecules. Recovery requires de novo enzyme synthesis (~days to weeks).
• Recommended cycle: Community standard is 4-12 weeks max during AAS cycle or PCT context, then off. Continuous chronic use beyond 12 weeks is poorly characterized and risks compounding bone/lipid harms.
• Reset protocol: Stop arimistane → aromatase activity returns over 1-3 weeks as new enzyme is synthesized; E2 typically rebounds to baseline over 2-4 weeks. Reversible-AI (anastrozole) reset is faster (days); suicide-AI reset is slower (weeks).
• Long-term tolerance / chronic-use concerns: Cumulative bone density loss + lipid drift apply to all AIs at chronic dosing. Periodic AI holiday is the prudent default.

Synergistic with (clinical contexts — limited because there is no clinical context for arimistane specifically)

• Cycle-adjunct context: Used alongside aromatizing AAS (testosterone, dianabol, anadrol) to manage E2 elevation. Same logic as anastrozole/exemestane in this role — arimistane is the supplement-grade alternative to those Rx options.
• HCG (during cycle): Sometimes co-administered to maintain testicular function; HCG keeps Leydig cells active while AI manages aromatization
• TRT (testosterone cypionate / enanthate): AI is added when TRT-induced E2 climbs symptomatically — but pharma-grade exemestane or anastrozole is a better choice than supplement-grade arimistane for managed TRT contexts (precise dosing, RCT support, clinician familiarity)

Avoid stacking with

• Other aromatase inhibitors (anastrozole, letrozole, exemestane): Redundant; combined AI use can crash E2 to severe-deficiency phenotype. Exemestane in particular is mechanistically identical (suicide AI) — stacking the two is irrational.
• SERMs (tamoxifen, raloxifene, enclomiphene, clomiphene) without clinical supervision: Combined ER blockade + aromatase blockade can crash tissue-level E2 to severe-deficiency phenotype. Joint pain, bone loss, lipid disruption, mood crash compound.
• Heavy alcohol use: Hepatic burden (especially in supplement-category context where contamination cannot be ruled out) + alcohol independently increases aromatase activity (confounds dose-response).
• Other "test booster" supplements claiming AI activity (DAA, fadogia, tongkat, eurycoma): Mechanisms either redundant or not credible in the eugonadal-male context; stacking adds noise without controlled benefit
• Estrogen replacement / phytoestrogen-heavy interventions: Mechanism conflict — defeats the purpose of the AI
• Statins: Lipid disruption from AI compounds with statin context — coordinate with prescriber if used together (rare in 20yo population)

Neutral / safe co-administration (theoretical, no PK studies)

• Most non-hormonal nootropics in the canonical stack: Modafinil, citicoline, NAC, magnesium, fish oil, theanine, rhodiola, curcumin, beta-alanine, creatine — no obvious PD/PK conflict
• Caffeine: No expected interaction
• Bromantane, Adamax/Semax, Selank: No PK conflict; PD non-overlapping
• D3 + K2 + calcium: Bone protection adjunct (relevant if AI ever chronic) — same role as in anastrozole/exemestane chronic-use protocols

CYP enzymes affected by arimistane: Not characterized in published literature. Class extrapolation from exemestane suggests minor CYP3A4 / CYP4A involvement; not expected to be a significant clinical DDI driver, but data is absent.

• CYP19A1 (aromatase) polymorphisms: Same applicability as anastrozole/exemestane — variants modulate baseline aromatase activity and likely modulate AI response magnitude. No arimistane-specific pharmacogenomic data.
• ESR1, ESR2 (estrogen receptors): Variants affect tissue response to declining E2 (joint pain susceptibility, bone loss steepness, mood effect magnitude). Not clinical-grade dosing guidance for any AI.
• UGT / CYP3A4 polymorphisms: Likely minor metabolic role; not clinically dose-determining.
• Practical note for the user: None applicable — he's not using arimistane. If ever indicated, his 23andMe results would be informational background, not deterministic.

For the user: sourcing is trivially easy if ever desired (any supplement retailer or research-chem vendor) — but the right answer is "don't use it; if you ever need an AI, use pharma-grade exemestane or anastrozole." The blocker is indication, not access; and the supplement-grade form is dominated on every axis by the pharma-grade options.

Baseline

• Estradiol (sensitive E2 assay, LC-MS/MS preferred — NOT standard immunoassay) — critical
• Total T, free T, SHBG, LH, FSH — full HPG panel
• Lipid panel (LDL, HDL, triglycerides) — baseline before AI-induced changes
• CMP (LFTs, kidney function) — baseline
• CBC — baseline
• Symptom inventory — joint pain, libido, mood baseline
• Blood pressure — baseline (relevant for any cycle/TRT context)

During use

• E2 (sensitive assay) at 4 weeks, 12 weeks — primary dose-titration biomarker; target 20-40 pg/mL for TRT-adjunct context (if hypothetically used in that role)
• Total T, free T at 4-12 weeks — confirm not over-correcting
• Lipid panel at 12 weeks — LDL/HDL drift surveillance
• LFTs at 12 weeks — designer-supplement category warrants slightly higher hepatic surveillance vigilance
• Blood pressure — periodic
• Joint comfort inventory — first AI-related signal in many users
• Symptom diary — libido, mood, energy, sleep, dryness signs

Post-discontinuation

• E2, T at 4-6 weeks post-stop — confirm rebound to baseline (longer-window than reversible AIs because of suicide-inhibitor enzyme-resynthesis kinetics)
• Lipid panel at 12 weeks post-stop — confirm normalization